Elevated glutamate impedes anti-HIV-1 CD8 + T cell responses in HIV-1-infected individuals on antiretroviral therapy.
You-Yuan WangCheng ZhenWei HuHui-Huang HuangYan-Jun LiMing-Ju ZhouJing LiYu-Long FuPeng ZhangXiao-Yu LiTao YangJin-Wen SongXing FanJun ZouSi-Run MengYa-Qin QinYan-Mei JiaoRuonan XuJi-Yuan ZhangChun-Bao ZhouJin-Hong YuanLei HuangMing ShiLiang ChengFu-Sheng WangChao ZhangPublished in: Communications biology (2023)
CD8 + T cells are essential for long-lasting HIV-1 control and have been harnessed to develop therapeutic and preventive approaches for people living with HIV-1 (PLWH). HIV-1 infection induces marked metabolic alterations. However, it is unclear whether these changes affect the anti-HIV function of CD8 + T cells. Here, we show that PLWH exhibit higher levels of plasma glutamate than healthy controls. In PLWH, glutamate levels positively correlate with HIV-1 reservoir and negatively correlate with the anti-HIV function of CD8 + T cells. Single-cell metabolic modeling reveals glutamate metabolism is surprisingly robust in virtual memory CD8 + T cells (TVM). We further confirmed that glutamate inhibits TVM cells function via the mTORC1 pathway in vitro. Our findings reveal an association between metabolic plasticity and CD8 + T cell-mediated HIV control, suggesting that glutamate metabolism can be exploited as a therapeutic target for the reversion of anti-HIV CD8 + T cell function in PLWH.